Abstract
Safe and effective use of viral vectors for gene therapeutics requires versatile control over their delivery to target sites in human subjects. We have developed a strategy for the creation of adenoviral vectors that possess conditional infectivity. The adenoviral vectors used were inactivated chemically such that they had little or no ability to infect cells. However, when such chemically inactivated adenoviral vectors were conjugated to the surfaces of appropriate microbeads and the resulting adenovirus-microbead conjugates were provided with the ability to associate stably with cells, the infectivity of these adenoviral vectors was restored. For certain target cell lines, the infectivity of such adenovirus-microbead conjugates became even higher than that of free, unmodified adenoviral vectors. As a result of the chemical inactivation of viral infectivity, any adenoviral particles that become free from the microbeads should be noninfectious. Thus, these adenoviral vectors have an infectivity that is conditional: They can only infect cells, to which their microbead conjugates come into stable contact. These results lay the groundwork for the creation of targetable adenovirus-microbead conjugates with greater efficacy and safety as delivery agents for gene therapeutics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bilbao G, Gomez-Navarro J, Curiel DT . Targeted adenoviral vectors for cancer gene therapy. Adv Exp Med Biol 1998; 451: 365–374.
Curiel DT . Strategies to adapt adenoviral vectors for targeted delivery. Ann NY Acad Sci 1999; 886: 158–171.
Cannon PM, Anderson WF . Retroviral vectors for gene therapy. In: Templeton NS, Lasic DD (eds). Gene Therapy. Therapeutic Mechanisms and Strategies. Marcel Dekker: New York, NY, 2000, pp 1–16.
Raynolds PN, Curiel DT . Strategies to adapt adenoviral vectors for gene therapy applications: targeting and integration. In: Friedmann T (ed). The Development of Human Gene Therapy. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1999, pp 111–130.
Hackett NR, Crystal RG . Adenovirus vectors for gene therapy. In: Templeton NS, Lasic DD (eds). Gene Therapy. Therapeutic Mechanisms and Strategies. Marcel Dekker: New York, NY, 2000, pp 17–40.
Vile RG, Russell SJ, Lemoine NR . Cancer gene therapy: hard lessons and new courses. Gene Therapy 2000; 7: 2–8.
Monahan PE, Samulski RJ . AAV vectors: is clinical success on the horizon? Gene Therapy 2000; 7: 24–30.
Wolfe D, Goins WF, Fink DJ, Glorioso III JC . Design and use of herpes simplex viral vectors for gene therapy. In: Templeton NS, Lasic DD (eds). Gene Therapy. Therapeutic Mechanisms and Strategies. Marcel Dekker: New York, NY, 2000, pp 81–108.
Kay MA, Glorioso JC, Naldini L . Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nature Med 2001; 7: 33–40.
Ponnazhagan S et al. Adeno-associated virus for cancer gene therapy. Cancer Res 2001; 61: 6313–6321.
Nicklin SA, Baker AH . Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Curr Gene Ther 2002; 2: 273–293.
Legrand V et al. Transductional targeting with recombinant adenovirus vectors. Curr Gene Ther 2002; 2: 323–339.
St George JA . Gene therapy progress and prospects: adenoviral vectors. Gene Therapy 2003; 10: 1135–1141.
Thomas CE, Ehrhardt A, Kay MA . Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346–358.
Büning H et al. Receptor targeting of adeno-associated virus vector. Gene Therapy 2003; 10: 1142–1151.
Barbara G et al. Interleukin 10 gene transfer prevents experimental colitis in rats. Gut 1999; 46: 344–349.
Fechner H et al. Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Therapy 2000; 7: 1954–1968.
Huard J et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Therapy 1995; 2: 107–115.
Wirtz S, Galle PR, Neurath MF . Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure. Gut 1998; 44: 800–807.
Schellingerhout D, Rainov NG, Breakefield XO, Weissleder R . Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Therapy 2000; 7: 1648–1655.
Gelse K et al. Fibroblast-mediated delivery of growth factor complementary DNA into mouse joints induces chondrogenesis but avoids the disadvantages of direct viral gene transfer. Arthritis Rheum 2001; 44: 1943–1953.
Cichon G et al. Titer determination of Ad5 in blood: a cautionary note. Gene Therapy 2003; 10: 1012–1017.
Pandori MW, Hobson DA, Sano T . Adenovirus-microbead conjugates possess enhanced infectivity: a new strategy for localized gene delivery. Virology 2002; 299: 204–212.
Scherer F et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Therapy 2002; 2: 102–109.
Mah C et al. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol Ther 2002; 6: 106–112.
Hobson DA, Pandori MW, Sano T . In situ transduction of target cells on solid surfaces by immobilized viral vectors. BioMed Central Biotechnol 2003; 3: 4.
Green NM . Avidin. Adv Protein Chem 1970; 29: 85–133.
Green NM . Avidin and streptavidin. Methods Enzymol 1990; 184: 51–60.
Sano T et al. Molecular engineering of streptavidin. Ann NY Acad Sci 1996; 799: 383–390.
Pandori MW et al. Photochemical control of the infectivity of adenoviral vectors using a novel photocleavable biotinylation reagent. Chem Biol 2002; 5: 567–573.
Shenk T . Adenoviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM (eds). Fundamental Virology, 3rd edn. Lippincott-Raven Publishers: Philadelphia, PA, 1996, pp 979–1016.
Vellekapm G et al. Empty capsids in column-purified recombinant adenovirus preparations. Human Gene Ther 2001; 12: 1923–1936.
Bergelson JM et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320–1323.
Tomko RP, Xu R, Philipson L . HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352–3356.
Roelvink PW et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998; 72: 7909–7915.
Ebbinghaus C et al. Functional and selective targeting of adenovirus to high-affinity Fcγ receptor I-positive cells by using a bispecific hybrid adapter. J Virol 2001; 75: 480–489.
Alemany R, Curiel DT . CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Therapy 2001; 8: 1347–1353.
Lis H, Sharon N . Lectins as molecules and as tools. Annu Rev Biochem 1986; 55: 35–67.
Sharon N, Lis H . Lectins as cell recognition molecules. Science 1989; 246: 227–234.
Sharon N, Lis H . Lectins – proteins with a sweet tooth: functions in cell recognition. Essays Biochem 1995; 30: 59–75.
Lis H, Sharon N . Lectins: Carbohydrate-specific proteins that mediate cellular recognition. Chem Rev 1998; 98: 637–674.
Acknowledgements
We thank Dr Fred Winston for access to his light/fluorescence microscope and for helpful suggestions on microscopic analysis. We also thank Dr Yuwadee Watanapokasin for help with quantitative PCR analysis. MWP was supported by a postdoctoral fellowship from the US Army Prostate Cancer Research Program, Department of Defense (DAMD17-99-9510), and by a training grant from the National Cancer Institute (CA59367; awarded to Dr Melvin E Clouse). This work was supported, in part, by grants from the National Cancer Institute (CA86262) and the US Army Breast Cancer Research Program, Department of Defense (DAMD17-03-1-0192).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pandori, M., Sano, T. Chemically inactivated adenoviral vectors that can efficiently transduce target cells when delivered in the form of virus-microbead conjugates. Gene Ther 12, 521–533 (2005). https://doi.org/10.1038/sj.gt.3302420
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302420
Keywords
This article is cited by
-
Inhibition of anaerobic probiotics on colorectal cancer cells using intestinal microfluidic systems
Science China Chemistry (2018)
-
Enhanced transduction of colonic cell lines in vitroand the inflamed colon in mice by viral vectors, derived from adeno-associated virus serotype 2, using virus-microbead conjugates bearing lectin
BMC Biotechnology (2007)